NCT07310264RecruitingPhase 1
Research into the safety of a new agent (AX-5006) in people with and without Parkinson's disease.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Aug 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- First submitted
- 1 Sept 2025
- Start date
- 27 Oct 2025
- Lead sponsor
- Vertero Therapeutics Inc.
- Diseases
- Parkinson disease
- EU CT number
- 2025-523254-14-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 108
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research Coordinator of this site? Confirm its status | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.